Comparative Pharmacology
Head-to-head clinical analysis: COMPAZINE versus TRANSDERM SCOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPAZINE versus TRANSDERM SCOP.
COMPAZINE vs TRANSDERM SCOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the vestibular system, gastrointestinal tract, and central nervous system, inhibiting vagal nerve activity and preventing motion-induced nausea and vomiting.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
One transdermal patch (1 mg/72 hours) applied to the hairless area behind the ear at least 4 hours before anticipated exposure; replace every 72 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
The terminal elimination half-life of scopolamine is approximately 9.5 hours (range 6-12 hours) following transdermal administration. In elderly patients, half-life may be prolonged to up to 20 hours.
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Scopolamine is extensively metabolized; about 50% of a dose is excreted renally as metabolites and unchanged drug, with less than 10% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 30-40% of the dose.
Category C
Category C
Antipsychotic (Phenothiazine) / Antiemetic
Antiemetic